HOWL - יחס חוב להיוון בספרים Werewolf Therapeutics Inc.

Werewolf Therapeutics (HOWL) develops innovative cytokines using PREDATOR technology for the targeted destruction of tumors. This debt-to-market cap chart clearly demonstrates financial stability, where the value 0.00 captures the metric level. The current R&D stage, characterized by a lack of sales, increases research expenses. However, the fierce competition with pharma behemoths for scientific priority creates risks of devaluation for the startup's developments.

This indicator assesses the business's dependence on borrowed funds relative to the market value of its equity. By analyzing the total debt-to-market capitalization ratio on GURU.Markets, an investor can track credit load dynamics based on daily asset revaluations. The metric is calculated as the ratio of total liabilities to the company's current market value. For Werewolf Therapeutics (HOWL), this is critical, as financing the aggressive development of the PREDATOR platform requires a balance between debt and capitalization. The biotech's high scientific productivity must be supported by a sustainable resource structure.